Huadong Medicine Co.,Ltd. (000963.SZ) has announced that certain of its products and partnered products have been included in the new version of the drug catalog and the new version of the commercial insurance innovative drug catalog.

Mefatinib Maleate Tablets, produced by the company's wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has been included in the negotiated drug section during the agreement period.

The partnered product Prusogliptin Tablets has completed its renewal, with the payment standard and payment scope remaining unchanged. Tacrolimus Granules has been adjusted to routine catalog management, with the payment scope remaining the same as the previous version of the drug catalog. The partnered product Zevor-cel Injection continues to be included in the new version of the commercial insurance innovative drug catalog.